Stockscreener 앱 받기
30.36
1.07%
0.32
시간 외 거래:
30.36
전일 마감가:
$30.04
열려 있는:
$30.6
하루 거래량:
3.31M
Relative Volume:
1.70
시가총액:
$4.85B
수익:
$616.29M
순이익/손실:
$447.18M
주가수익비율:
10.93
EPS:
2.7771
순현금흐름:
$-24.99M
1주 성능:
+12.69%
1개월 성능:
+3.05%
6개월 성능:
-6.21%
1년 성능:
-28.51%
1일 변동 폭
$29.12
$32.23
1주일 범위
$26.93
$32.47
52주 변동 폭
$25.28
$46.48
TG테라퓨틱스사 Stock (TGTX) Company Profile
명칭
Tg Therapeutics Inc
전화
(212) 554-4484
주소
2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY
Compare TGTX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TGTX
Tg Therapeutics Inc
|
30.36 | 4.80B | 616.29M | 447.18M | -24.99M | 2.7771 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
TG테라퓨틱스사 Stock (TGTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-06 | 재개 | H.C. Wainwright | Buy |
| 2025-07-10 | 재개 | Goldman | Neutral |
| 2024-10-29 | 개시 | TD Cowen | Buy |
| 2023-08-02 | 업그레이드 | Goldman | Sell → Neutral |
| 2023-06-26 | 재개 | Jefferies | Buy |
| 2022-05-20 | 개시 | BofA Securities | Underperform |
| 2022-02-23 | 재확인 | B. Riley Securities | Buy |
| 2021-11-15 | 다운그레이드 | Goldman | Neutral → Sell |
| 2021-04-20 | 개시 | Goldman | Neutral |
| 2021-04-19 | 재확인 | H.C. Wainwright | Buy |
| 2020-09-01 | 개시 | JP Morgan | Overweight |
| 2020-08-11 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-05 | 개시 | Evercore ISI | Outperform |
| 2020-01-17 | 재확인 | H.C. Wainwright | Buy |
| 2019-11-27 | 재개 | B. Riley FBR | Buy |
| 2019-02-06 | 재개 | Jefferies | Buy |
| 2018-09-25 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2018-03-09 | 재확인 | B. Riley FBR, Inc. | Buy |
| 2017-12-01 | 재개 | B. Riley FBR, Inc. | Buy |
| 2017-11-14 | 재개 | H.C. Wainwright | Buy |
| 2017-04-25 | 개시 | Jefferies | Buy |
| 2017-03-06 | 재확인 | FBR & Co. | Outperform |
| 2016-10-06 | 재개 | Brean Capital | Buy |
| 2016-05-27 | 개시 | SunTrust | Buy |
| 2015-12-01 | 개시 | FBR Capital | Outperform |
| 2015-09-09 | 개시 | Raymond James | Strong Buy |
| 2015-08-12 | 재개 | H.C. Wainwright | Buy |
| 2015-06-19 | 재확인 | Brean Capital | Buy |
| 2014-12-11 | 재확인 | ROTH Capital | Buy |
| 2014-12-10 | 재확인 | ROTH Capital | Buy |
모두보기
TG테라퓨틱스사 주식(TGTX)의 최신 뉴스
TG Therapeutics (TGTX) Secures $750 Million Credit Facility - GuruFocus
TG Therapeutics secures $750M credit facility with Blue Owl By Investing.com - Investing.com Canada
TG Therapeutics (TGTX) Secures $750M Credit Facility, Expands Sh - GuruFocus
TG Therapeutics Receives $500 Million in New Capital From Blue Owl, Increases Share Buyback - marketscreener.com
TG Therapeutics secures an additional $500 million in non-dilutive capital from Blue Owl and expands share repurchase program to $300 million - marketscreener.com
TG Therapeutics Secures An Additional $500 Million In Non-Dilutive Capital From Blue Owl And Expands Share Repurchase Program To $300 Million - TradingView
TG Therapeutics Secures an Additional $500 Million in - GlobeNewswire
Penn Capital Management Company LLC Grows Stock Position in TG Therapeutics, Inc. $TGTX - MarketBeat
TG Therapeutics Analysis: Strong Clinical Data Boost Briumvi Prospects - timothysykes.com
TG Therapeutics (NASDAQ:TGTX) Shares Up 7.9%Here's What Happened - MarketBeat
How BRIUMVI’s Strong High‑Risk MS Data At TG Therapeutics (TGTX) Has Changed Its Investment Story - simplywall.st
TGTX SEC FilingsTg Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
TGTX Q4 earnings lag estimates, Briumvi sales drive top line - MSN
TG Therapeutics to present BRIUMVI data at neurology meeting - Investing.com Nigeria
A Look At TG Therapeutics (TGTX) Valuation After New BRIUMVI Efficacy Data In Relapsing Multiple Sclerosis - simplywall.st
TG Therapeutics Inc (NASDAQ:TGTX) Presents a Compelling Momentum Case with Strong Growth and Technical Setup - ChartMill
TG Therapeutics, Inc. (NASDAQ:TGTX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
(TGTX) Risk Channels and Responsive Allocation - Stock Traders Daily
Briumvi momentum leads to strong execution for TG Therapeutics (TGTX) - MSN
BRIUMVI Momentum Leads to Strong Execution for TG Therapeutics (TGTX) - Yahoo Finance
WINTON GROUP Ltd Buys 113,951 Shares of TG Therapeutics, Inc. $TGTX - MarketBeat
TG Therapeutics, Inc.Common Stock (NQ: TGTX - The Chronicle-Journal
10 Most Shorted Biotech Stocks to Buy According to Hedge Funds - Insider Monkey
Is TG Therapeutics (TGTX) Pricing Reflecting Its Mixed Multi Year Share Performance? - Yahoo Finance
TGTX: Positive Phase 3 Analysis Results for Briumvi in Treating Multiple Sclerosis - GuruFocus
Data Published in Neurology and Therapy Demonstrate - GlobeNewswire
Bank of America Securities bearish on TG Therapeutics (TGTX) post earnings - MSN
Data Published in Neurology and Therapy Demonstrate Significant Reductions in Relapse and MRI Activity with BRIUMVI® in People with Highly Active Relapsing Multiple Sclerosis - Sahm
How Investors Are Reacting To TG Therapeutics (TGTX) Adding Azer-cel Milestone to Its MS Portfolio - Yahoo Finance
Azer Cel Milestone Broadens TG Therapeutics Autoimmune Pipeline And Valuation Story - Yahoo Finance
Assessing TG Therapeutics (TGTX) Valuation After BRIUMVI‑Led Earnings And Autoimmune Pipeline Updates - Yahoo Finance
Bank of America Securities Bearish on TG Therapeutics (TGTX) Post Earnings - Finviz
TGTX (TG Therapeutics) Total Assets : $1,063.3 Mil (As of Dec. 2025) - GuruFocus
Is TG Therapeutics Inc. (NKB2) stock included in top ETFs2026 Buyback Activity & AI Forecast Swing Trade Picks - Naître et grandir
TG Therapeutics to present BRIUMVI data at neurology meeting By Investing.com - Investing.com Canada
TG Therapeutics (TGTX) sees price target drop from JPMorgan - MSN
TG Therapeutics, Inc. $TGTX Stake Cut by Teachers Retirement System of The State of Kentucky - MarketBeat
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting - Bitget
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting - The Manila Times
TG Therapeutics Azer Cel Milestone Adds Depth To Autoimmune Valuation Story - Sahm
Reports Suggest TG Therapeutics May Be Scaling Back Operations Amid Speculation on CafePharma Forum - geneonline.com
TG Therapeutics Q2 EPS Estimate Lowered by HC Wainwright - MarketBeat
TG Therapeutics Q4 EPS Forecast Lowered by HC Wainwright - MarketBeat
Analysts Offer Insights on Healthcare Companies: Astrana Health (ASTH) and TG Therapeutics (TGTX) - The Globe and Mail
TG Therapeutics Milestone With Azer Cel Adds New Dimension To Growth Story - Sahm
TG Therapeutics Confronts Rising AI Regulatory and IP Risks That Could Pressure Costs, Strategy, and Growth - The Globe and Mail
Precision BioSciences (DTIL) Hits Milestone, Secures $7.5M from TG Therapeutics - GuruFocus
TG Therapeutics, Inc. (TGTX) Growth Potential: Navigating A 47.65% Upside In Biotech - DirectorsTalk Interviews
Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis - Yahoo Finance
HC Wainwright Raises Earnings Estimates for TG Therapeutics - MarketBeat
Is TG Therapeutics’ 2025 Earnings Miss and BRIUMVI Guidance Shift Altering The Investment Case For TGTX? - simplywall.st
TG테라퓨틱스사 (TGTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):